###
中国临床研究英文版:2026,39(9):1316-1333
摘要
本文已被:浏览 428次   下载 415次
Received:August 07, 2026   Published Online:September 24, 2026
中文摘要: 我国糖尿病流行病学形势严峻,患病率持续攀升。临床现状显示,逾80%的患者并非单纯血糖异常,而是合并高血压、血脂异常、超重/肥胖、高尿酸血症及代谢相关脂肪性肝病等多重代谢紊乱。上述因素之间存在显著的协同致病效应,导致患者发生心肾不良事件及全因死亡的风险叠加。近年来,“代谢共管”与“综合达标”的理念虽日益受到重视,但临床实践仍缺乏整合代谢共病、急慢性并发症及相关合并症的一体化筛查、精准化诊疗与全周期随访标准化指导。本专家建议参考国内外最新糖尿病与代谢共管指南,系统梳理了涵盖“筛查预防—诊断评估—治疗康复—随访管理”全链条的临床核心问题。旨在为制定个体化干预方案提供依据,推动糖尿病管理模式由单一血糖控制向多代谢指标综合达标转变,进而降低致残率与致死率,助力提升糖尿病慢病管理的标准化与同质化水平。
中文关键词: 糖尿病  代谢疾病  综合达标  并发症  合并症
Abstract:The epidemiological landscape of diabetes mellitus in China remains severe,with a continuously rising prevalence. Clinically,over 80% of patients present with multiple metabolic abnormalities beyond hyperglycemia alone,including hypertension,dyslipidemia,overweight/obesity,hyperuricemia,and metabolic-associated fatty liver disease.These factors exert synergistic pathogenic effects,compounding the risks of adverse cardiovascular and renal events as well as all-cause mortality. Although the concepts of“metabolic co-management”and“comprehensive target achievement”have gained increasing recognition,clinical practice still lacks standardized guidelines that integrate holistic screening,precision diagnosis and treatment,and full-cycle follow-up for metabolic comorbidities,acute and chronic complications,and related conditions. Referencing the latest domestic and international guidelines on diabetes and metabolic co -management,this expert recommendation systematically reviews key clinical issues across the entire care continuum-from screening and prevention,diagnosis and assessment,to treatment and rehabilitation,and follow-up management. It aims to provide a basis for individualized management strategies,facilitate a paradigm shift from isolated glycemic control to the comprehensive optimization of multiple metabolic targets,reduce disability and mortality,and ultimately enhance the standardization and homogenization of chronic diabetes management.
文章编号:     中图分类号:R587.1    文献标志码:A
基金项目:江苏省重点研发计划社会发展项目(BE2023774);国家四大慢病国家科技重大专项 (2024ZD0523200)
引用文本:


Scan with WeChat

Scan with WeChat